Verigene II

Device Luminex Corporation
Total Payments
$710,703
Transactions
7
Doctors
0
Companies
1

Payment Trends by Year

Year Amount Transactions Doctors
2023 $710,703 7 0

Payments by Nature

Nature of Payment Amount Transactions Share
Unspecified $710,703 7 100.0%

Research Studies & Clinical Trials

Study Name Sponsor Amount Doctors
ATL-RTI-01 Verigene II RSP/RSP Expanded Luminex Corporation $633,588 0
ATL-CNS-01 VERIGENE II CNS Flex Panel Luminex Corporation $50,116 0
ATL-EPF-01Verigene II GI/GI-2 Luminex Corporation $21,169 0
ATL-CSN-01 Verigine II CNS Flex Assay Luminex Corporation $3,294 0
ATL-EPF-01 Verigene II GI/GI-2 Luminex Corporation $1,860 0
VER-BCY-01 VERIGENE II BC Yeast Assay Luminex Corporation $675.00 0

Top Doctors Receiving Payments for Verigene II

Doctor Specialty Location Total Records
Unknown Los Angeles, CA $710,703 7

About Verigene II

Verigene II is a device associated with $710,703 in payments to 0 healthcare providers, recorded across 7 transactions in the CMS Open Payments database. The primary manufacturer is Luminex Corporation.

Payment data is available from 2023 to 2023. In 2023, $710,703 was paid across 7 transactions to 0 doctors.

The most common payment nature for Verigene II is "Unspecified" ($710,703, 100.0% of total).

Verigene II is associated with 6 research studies, including "ATL-RTI-01 Verigene II RSP/RSP Expanded" ($633,588).